BioSpring

BOSTON--( BUSINESS WIRE )-- Labviva , the AI-driven life sciences digital marketplace that simplifies and scales purchasing processes, announced today that it has secured $20 million in Series A financing led by Biospring Partners, with participation from existing investors Senator Investment Group, B Capital Group, and Glasswing Ventures. The Series A funding brings the total amount raised since inception to $30 million. The funding will be used to accelerate deployment of Labviva’s platform at a number of global pharmaceutical and academic customers. Labviva provides an easy-to-use SaaS platform and marketplace that unifies the interface for product discovery and procurement and seamlessly connects suppliers, purchasers, allowing scientists to make better purchasing decisions. The company will also use the funding to expand its global footprint and launch new and complementary product lines. In addition, Jennifer Lum, Co-Founder & Managing Partner, Biospring Partners will join the Board of Directors at Labviva. Labviva’s B2B e-commerce marketplace enables life sciences and research organizations to manage organizational purchasing and procurement to accelerate the pace of life science research. Driven by AI, Labviva’s platform integrates directly with leading procurement systems such as SAP Ariba, JAGGAER, Oracle Procurement Cloud, Microsoft Dynamics 365, and Coupa, to shorten implementation times and reduce the risk of research delays. The current purchasing process in life sciences is an inefficient, manual process, with slow internal approvals and a lack of choice and transparency. In this traditional model, purchasers have access to limited number of digital catalogs from one or two major distributors and a handful of other suppliers. The lack of product diversity in a purchasing catalog can cause a higher cost of purchasing and exposes buyers to supply chain disruptions with significant delay to research timelines. With Labviva, purchasing and procurement needs are met in a single software interface that is intuitive, scientist-centric and easy to set up. Labviva provides access to thousands of suppliers and over 15 million products, supports custom user, department, and location approval structures with notifications, and tracking and reporting tools to provide real-time visibility by integrating directly with buyer’s internal and third-party software solutions. “Our customers trust us to manage hundreds of millions of dollars in laboratory and research spend annually. Labviva helps manage a company’s spending, giving customers back control, with real-time purchasing insights to realize significant hard cost savings while providing the scientific and technical staff with the product content and scientific insight to improve the speed and quality of their product selection process,” said Siamak Baharloo, CEO & Co-Founder, Labviva. “By aggregating hundreds of product catalogs for a seamless search, discovery and shopping experience, our platform integrates with existing procurement systems, to empower the purchasing departments to take control of their spend, provide greater visibility of purchasing trends and increase compliance with procurement processes within a comprehensive and customized internal marketplace.” Early in its development, Labviva partnered with a global large pharma company and its suppliers to optimize its procurement processes, solving problems & addressing gaps through the utilization of Labviva’s platform. Labviva was able to enhance the client’s supply chain resiliency and provide scientists with self-sourcing capabilities through easy access to products from an expanded supplier base. “Labviva’s procurement solutions returned our organization’s focus to strategic initiatives and scientists to their core work by enhancing system and process agility and collaborating with internal groups and our key suppliers to address challenges,” said Director of Procurement, Global Large Pharma Company. “Labviva’s platform reduced our scientists’ workload through the development of a customized user interface and training program for order management activities.” Labviva was able to enhance supplier management capabilities through spend categorization and big data analysis, and increased transaction process efficiencies and catalog orders by aligning with different departments to consolidate catalog management services, with API integration with the global large pharma’s IT and its suppliers’ e-commerce systems. “We’re thrilled to support Labviva, as they revolutionize the life sciences procurement industry. Labviva is the only procurement solution built by scientists for scientists, with research outcomes considered at every step of the way,” said Jennifer Lum, Co-Founder & Managing Partner, Biospring. “Labviva has an immense market opportunity to create a new category around spend culture for life sciences companies and research organizations. With Labviva’s platform, companies can gain visibility with real-time spend insights to make informed decisions before approving purchases, not after.” Labviva provides a digital marketplace for life science companies and researchers, connecting suppliers of reagents, chemicals, and instrumentation. The team has created a unique relationship between scientific content and products across hundreds of brands and suppliers resulting in a seamless onboarding and purchasing experience. About Labviva Labviva is the largest life sciences digital marketplace that connects researchers with suppliers of reagents, chemicals, and instrumentation in an intuitive user-friendly platform that is built for scientists by scientists. Suppliers can easily manage their content of their products, and products are mapped into scientific applications, techniques and protocols. Our mission is to accelerate the pace of life science research by connecting suppliers, purchasing departments, and scientists through AI. We integrate with industry-leading procurement systems to shorten implementation times and accelerate life sciences research. For more information, visit www.labviva.com . Follow us on Twitter @labvivanews .

Nov. 16, 2021 12:00 UTC Ncardia forms strategic partnership with Kiniciti to build GMP capabilities to support iPSC cell therapy platforms and human cell-based in vitro discovery services GOSSELIES, Belgium & NEW YORK--(BUSINESS WIRE)--Ncardia, a leader in developing stem cell-based solutions for drug discovery and cell therapy, announced that it has secured more than $60 million in capital through a strategic partnership with Kiniciti, a U.S.-based investment platform focused on strengthening the cell and gene therapy ecosystem worldwide. Kiniciti is backed by Welsh, Carson, Anderson & Stowe (WCAS), a leading private equity firm investing in healthcare and technology, and Biospring Partners. The transaction gives Kiniciti a control stake in Ncardia to support growth and enhance capabilities spanning discovery to clinical programs to commercial production. This press release features multimedia. View the full release here: A leader in contract research, development and manufacturing of human-induced pluripotent stem cell-based solutions (iPSC), Ncardia’s capabilities include bio-reactor-based scalable manufacturing of iPSC derived cells, assay development, disease modeling, and cell-based screening. “We are thrilled to welcome Kiniciti as our strategic investment partner,” said Alain Parthoens, Ncardia’s Chairman. “Kiniciti is uniquely suited to help Ncardia expand globally and to support our planned investment into GMP capabilities for our iPSC-based cell therapy platforms.” “Combining Ncardia’s revolutionary, differentiated science with our ability to build global companies and supporting ecosystems will create significant value for therapeutic customers,” said Geoff Glass, CEO of Kiniciti. “We’re excited to make Ncardia the centerpiece of an ecosystem that we will build to ensure that cell therapies claim their rightful place in advancing human health. Through this partnership, Ncardia’s customers will benefit from the company’s expanded cGMP capabilities in cell therapy and more robust offerings in discovery services.” Ncardia has leveraged its diverse capabilities through a platform comprising multiple technologies and services to accommodate projects for various therapeutic modalities at any stage of development. “With this partnership, we can enhance our technology platforms with Kiniciti’s capital and deep expertise to create a strong and successful global iPSC leader,” said Ncardia Co-founder and CEO Stefan Braam, PhD. “We’ll do that on the drug discovery side by building additional human cellular models with the capability to predict whether drugs are safe and efficacious much earlier in the development process. In cell therapy, we’re going to help our customers with novel manufacturing technology that will create robust iPSC-based allogenic platforms in the immuno-oncology field.” While comparatively new in the cell therapy space, human iPSC initiatives have garnered considerable interest because of the incredible potential they hold for cell therapy companies. iPSC technology gives scientists the ability to reprogram a given skin or blood cell into a stem cell, which in turn can be differentiated into any target cell type of interest. That cell then can be further enhanced with custom cell engineering and edits to match customers’ needs. “A guiding principle in this partnership is to expand access to, and drive down the cost of, cell therapies for patients in need,” Mr. Glass said. “The only way that happens is by building robust, industrialized and scalable platforms. And that is precisely what we will accomplish through our partnership with Ncardia. We’re very excited to collaborate with Stefan and his team of experts, and we look forward to fulfilling iPSC’s potential to deliver better therapies to patients around the world.” About Ncardia Ncardia is a human iPSC technology company that operates worldwide with facilities, offices, and staff throughout Europe and North America. Ncardia is built on the belief that stem cell technology will help bring better therapies to patients faster. The company’s goal is to enable biopharmaceutical companies in drug discovery and cell therapy to accelerate their development processes through the integration of human iPSC technologies. For more information, visit ncardia.com. About Kiniciti Kiniciti, a platform company of leading private equity firm Welsh, Carson, Anderson & Stowe (WCAS) and Biospring Partners, invests in and partners with companies that have the potential to transform and strengthen the cell and gene therapy ecosystem. With a highly tailored, collaborative, and flexible investment and strategic support model, Kiniciti aims to ensure the promise of cell and gene therapeutics is delivered quickly and safely to patients worldwide. The company’s leadership team includes professionals experienced in investing in and building successful companies across the life sciences sector. For more information, visit kiniciti.com. About Welsh, Carson, Anderson & Stowe WCAS is a leading private equity firm focused on two target industries: technology and healthcare. Since its founding in 1979, the firm's strategy has been to partner with outstanding management teams and build value for its investors through a combination of operational improvements, growth initiatives and strategic acquisitions. WCAS has deep experience in acquiring founder-led businesses and corporate carve-outs. The firm has raised and managed funds totaling over $27 billion of committed capital. For more information, please visit .

Diet and wellness startup Noom led the charge of second-quarter 2021 funding rounds, taking home a whopping $540 million. In Q2 MobiHealthNews reported on 99 digital health deals worth roughly $6.2 billion. While this is a slight dip from Q1's recording-breaking $7.1 billion, it easily trumps 2020's Q2, which saw $2.44 billion in deals. In 2020, MobiHealthNews reported on 372 funding rounds worth approximately $13.8 billion. This year is sure to outpace last year. Read on for a list of Q2 funding details. Company Round/Series Amount (M) Investors What's it for What they do Noom Series F $540 Silver Lake led the round with participation from Oak HC/FT, Temasek, Novo Holdings, Sequoia Capital, RRE and Samsung Ventures. The company is looking to use the new funds to expand its focus area beyond weight loss. It said the new funds will help it address more conditions, including stress, anxiety, diabetes, hypertension and sleep. Historically, Noom has been focused on helping users lose weight and improve their fitness level. The company developed a tool that uses behavioral therapy to help users change their habits. Olive N/A $400 Vista Equity Partners led the round with participation from The Base10 Advancement Initiative. The new cash will be used to accelerate product development in order to reach new clients. Olive automates a range of tedious, high-volume administrative tasks for healthcare organizations. Capsule N/A $300 N/A The funds will go toward market expansion and technology updates. Capsule is a digital pharmacy. Collective Health Series F $280 The round was led by Health Care Service Corporation, with additional participation from new and existing investors, including DFJ Growth, Founders Fund, G Squared, Maverick Ventures, NEA, PFM Health Sciences, SoftBank Vision Fund 1, Sun Life and others. The San Francisco-based startup plans to use the funding to scale its platform. Collective Health brings together companies’ various health benefits into one platform to let employers manage their offerings while assisting employees to navigate their healthcare. Quanta Series D $245 Glenview Capital and Novo Holdings co-led the round. Other participating investors include BlackRock, Eldridge, Sands Capital, Millennium, Monashee Investment Management, Puhua Capital, Segulah Medical and Ancora, Orlando Health, Wellington Partners, btov, Seroba Life Sciences and The Grands The company plans to use the new capital to scale its global operations, specifically focusing on expanding its Beverly, Mass., facility and growing its leadership team. Quanta is a medtech company for dialysis care. Cue Health private investment $235 Investments were made by new backers Perceptive Advisors, MSD Capital and Koch Strategic Platforms, as well as by existing investors including Johnson & Johnson Innovation, Decheng Capital, CAVU Ventures, ACME Capital and others. The new capital will be used to accelerate Cue’s growth, the company said in its announcement. The San Diego-based startup’s lead product is the Cue Health Monitoring System, a molecular testing device designed for use in care settings, schools, homes and other places. AlayaCare Series D $225 The round was led by Generation Investment Management. Additional participants include Klass Capital, Inovia Capital, CDPQ and Investissement Québec. AlayaCare will use the funding to continue global expansion, hire additional staff and invest in new software offerings. The company’s home healthcare software products strive to meet the entire client life cycle from referrals and intake to billing and payroll. Insilico Medicine Series C $225 The round was led by Warburg Pincus and Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, Baidu Ventures, and new investors including CPE, OrbiMed, Mirae Asset Capital, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China and Sage Partners. The new money will go toward building up the company's therapeutic programs, with the goal of eventually being used in human clinical trials. Insilico Medicine is focused on using machine learning and artificial intelligence for drug research. Gympass N/A $220 The round was led by Softbank, General Atlantic, Moore Strategic Ventures, Kaszek and Valor Capital Group. The company said that the new funds will help its U.S. market as gyms and workplaces begin to go back to in-person attendance. Founded in 2012, Gympass works with employers to offer staff a monthly fitness pass that can be redeemed at gyms and different fitness studios. Lyra Health N/A $200 The round was led by Coatue. Sands Capital and the company’s existing investors also participated in the raise. Building off its recent partnership with ICAS World, Lyra is using the new capital to support the launch of its new international service options. Offered as a health benefit, the Lyra platform matches employees and their dependents to mental healthcare professionals and personalized evidence-based treatments. PathAI Series C $165 The round was co-led by D1 Capital Partners and Kaiser Permanente, with additional participation from General Atlantic, Tiger Global Management, 8VC, Adage, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners, Refactor Capital, and strategic partners Bristol-Myers Squibb Company, Labcorp and Merck Global Health Innovation Fund. With the new funds, PathAI plans to accelerate product development to expand its suite of applications beyond oncology and nonalcoholic steatohepatitis. It will also seek new partnerships with pharmaceutical and diagnostic organizations. PathAI is a Boston-based artificial intelligence pathology company. Monogram Health Series B $160 The round was round led by TPG Capital. Existing investors Frist Cressey Ventures, Norwest Venture Partners and Humana Inc. also participated in the raise. The investments will be used to fund company expansion, Monogram said in the release. The Nashville, Tennessee-based company partners with health plans to offer their members a range of renal care services. LetsGetChecked Series D $150 Casdin Capital led the investments with additional participation from CommonFund Capital, Illumina Ventures, Optum Ventures, Transformation Capital, HLM Venture Partners, Qiming Venture Partners USA and professional golfer Rory Mcllroy through Symphony Ventures. With the newly raised capital, LetsGetChecked plans to roll out new care pathways for patients with ailments and chronic conditions. It will do so through strategic investments into its core offerings. LetsGetChecked offers more than 100 types of at-home tests, including ones for sexual health, cholesterol, diabetes, thyroid and COVID-19. EDDA Technology N/A $150 Softbank Vision Fund 2, OrbiMed, 3W Fund, Morningside Ventures, Matrix Partners China, SBCVC, BOCGI, Trust Bridge and Draper Dragon. EDDA Technology CEO and President Dr. Jianzhong Qian said the proceeds from the funding round will be used to capture the untapped market for AI-powered surgical robots, such as hospitals in second- and third-tier cities in China. EDDA Technology, a consortium of health tech firms based in the U.S. and China, integrates artificial intelligence and robotics with precision surgery. Thirty Madison Series C $140 HealthQuest Capital led the round, with participation from Mousse Partners, Bracket Capital, Polaris Partners, Johnson & Johnson Innovation, Northzone and Greycroft. The company plans to use the new funds to expand its specialist-level care, including launching new brands focused on a variety of conditions. Through virtual doctor visits, users can order a range of drug treatments for each chronic condition it serves. Virta Health Series E $133 Tiger Global led the round. Virta plans to use the funds to grow its platform to reach more patients. Virta claims it can reverse Type 2 diabetes with its treatment program that combines tracking, coaching and remote monitoring capabilities with a nutrition-based ketogenic diet. Greenlight Guru strategic growth investment $120 JMI Equity The investment will enable accelerated product development, improved product capabilities and global expansion, according to the announcement. Greenlight Guru develops software specifically for the medical device industry to help companies navigate the regulatory approval process. Vida Health Series D $110 General Atlantic, Centene and AXA Venture Partners led the round with additional support from Ardea Partners, Ally Bridge Group, AME Cloud Ventures, Aspect Ventures, Canvas Ventures, Guidewell, NGP Capital and Workday Ventures. The company plans to put the new funding into growing its network of health coaches by adding new clinicians, mental health specialists and dieticians. Vida Health’s digital platform connects users with a personal health coach who guides them through their desired program. Aetion Series C $110 Warburg Pincus led the round, with participation from B Capital and Foresite Capital. The New York-based company is looking to use the funds to grow its business in Europe and the Asia Pacific region. It is also looking to build out its commercial team. The company works with biopharma companies, payers and regulatory agencies to help provide insights into real-world evidence. Caresyntax Series C $100 PFM Health Sciences LP led the round, and new investors Optum Ventures, Intel Capital, Lauxera Capital Partners, Vesalius Biocapital III, Arno Capital and Rezayat Investments, as well as existing investors IPF Partners, the Relyens Group and Surgical.AI also participated in the raise. The funding will be used to accelerate Caresyntax’s growth, conduct research and development for its AI technology, expand its platform and add to its employee base. The company’s platform utilizes artificial intelligence and real-world data from the operating room to provide actionable insights to the care team. Oura Health Series C $100 The round was led by the Chernin Group and Elysian Park, the investment arm of the L.A. Dodgers, and included new investors Temasek, JAZZ Venture Partners and Eisai. Returning backers Forerunner Ventures, Square, MSD Capital, Marc Benioff, Lifeline Ventures, Metaplanet Holdings and Next Ventures also participated in the round. Oura plans to spread the funds across its business and will invest in software and hardware, research and development, marketing and customer experience. Oura Ring is designed to be worn day and night to track the wearer’s health data at all times. Phil strategic growth investment $100 Warburg Pincus The startup plans to use the new funds to speed up the development of its products and grow its customer base. The company has developed a tool to automate physician, payer and pharmacy workflows while helping patients schedule refills. SWORD Health Series C $85 General Catalyst led the round with participation from BOND, Highmark Ventures, BPEA, Khosla Ventures, Founders Fund, Transformative Capital and Green Innovations. The company plans to continue to grow. SWORD Health is a digital musculoskeletal company. Florence Series C $80 Insight Partners led the round with participation from Fulcrum Equity Partners, Bee Partners and Flashpoint. The company plans to use the new funds to grow out its business and work with more clients. The company is focused on decentralized clinical trials. Its main function is helping connect pharma companies with study sites. Curefit private investment $75 Curefit entered into a partnership with Tata Digital Limited, a subsidiary of Tata Sons, for a private investment. The investment will allow Curefit to grow its tech-enabled fitness offerings while helping Tata Digital expand into the proactive health management space. Curefit is an Indian fitness, health and lifestyle brand. Brightline Series B $72 GV led the round with additional participation from Optum Ventures, 7wireVentures, Gaingels and Debra Lee, the chairman and CEO emeritus of BET Networks. The funding will be used for company expansion and to support a number of new business initiatives. Designed to be a comprehensive behavioral health platform for kids, teens and their families, Brightline offers virtual therapy, medication support, on-demand chatting with coaches, digital resources for parents and caregivers, and speech therapy. Headway Series B $70 Andreessen Horowitz led the round with participation from Thrive, GV and Accel. With the new capital, Headway will grow its team to more than 300 people as it works toward scaling to full national coverage. Headway operates a platform connecting patients to in-network therapists and private practice therapists to insurance companies. Papa Series C $60 Tiger Global Management led the round. Papa plans to use the newly added capital to continue its growth. Papa got its start in 2017 by matching young adults, called Papa Pals, with seniors to provide assistance and companionship. Adela Series A $60 F-Prime Capital led the round with additional support from OrbiMed, Deerfield Management, Decheng Capital and RA Capital Management. Adela will use the funding to support the commercialization of its technology. The Toronto-based company’s platform uses genome-wide methylation analysis technology for the early detection of cancer. Transcarent Series B $58 General Catalyst and 7wireVentures co-led the round with participation from new investors Merck Global Health Innovation Fund, Kleiner Perkins, Leaps by Bayer, GreatPoint Ventures and Threshold Ventures, along with existing investors Alta Partners and Jove Equity Partners. Transcarent plans to put the funds into expanding its risk-based bundle of digital health services. Transcarent is a healthcare platform for the self-insured employer market led by Livongo founder Glen Tullman. Tendo Systems Series B $50 Lux Capital led the round, and General Capital participated. The company did not specify what the new funding would be used for. The digital engagement platform and connected applications aim to join patients and providers throughout the care experience. DrFirst equity investment $50 Sixth Street Growth The investment from Six Street Growth will go toward continuing its business growth. The Rockville, Maryland-based company provides a range of software solutions for stakeholders across the healthcare spectrum, including providers, payers and life science companies. Wheel Series B $50 Lightspeed Ventures led the round, and existing investors CRV, Silverton Partners, Tusk Venture Partners and J.P. Morgan also took part in the round, along with new investor Future Shape. This investment will enable Wheel to continue growing. Specifically, the company plans to invest in its technology and clinician networks as well as growing its team and partnering with additional companies. Wheel provides two main services: telehealth staffing opportunities for clinicians and a scalable virtual care platform for companies. Helix Series C $50 The round was led by Warburg Pincus, DFJ Growth, Kleiner Perkins Caufield Byers, Mayo Clinic and Temasek. This new infusion of cash will go toward growing the company's population genomics tool, which is used by life science companies and payers, as well as for public health efforts for COVID-19 surveillance. Helix is able to analyze customers' DNA and give them insights into their health and heritage, based on the user request. Atonarp Series D $50 The round was led by WRVI Capital and supported by Furukawa Electric, Japan Post Investment, Boscolo Intervest, ATI Korea and Banner Industries. Atonarp said the new funds will be used to expand its operations "to meet growing customer demand in its current markets." Founded in 2010, Atonarp produces digital molecular diagnostic solutions for various industries, including pharmaceuticals, semiconductor manufacturing, industrial process control and life sciences. Unmind Series B $47 EQT led the round, with participation from Sapphire Ventures, Project A, Felix Capital and True. The company is looking to use this Series B money to expand and build out its team. The startup is focused on supporting employees experiencing signs of mental illness. The tool provides mental health assessments to help employees track their mental health over a period of time. Current Health Series B $43 Northpond Ventures led the round, along with LRVHealth, OSF HealthCare, Section 32, Elements Health Ventures and existing investors. The funds will go toward company growth. Current Health’s remote patient monitoring devices, paired with its platform, collect and monitor users' vital signs to enable preventative care. The Pill Club Series B extension $42 The extension was led by Base 10, with additional participation from ACME, GV, Shasta Ventures, VMG, Uber’s Dara Khosrowshahi, Honey’s George Ruan and iGlobe. The new capital will be used to expand The Pill Club’s services and hire new talent. The Pill Club allows users to order birth control online and have it sent directly to their homes. Firefly Health Series B $40 Andreessen Horowitz led the round with participation from previous investors F-Prime Capital and Oak HC/FT. With the newly raised capital, Firefly plans to enter the employer-sponsored market with the launch of its health plan offering. When people sign up for the platform, they select a comprehensive care team that includes a primary care physician, nurse practitioner, health guide and behavioral health specialist. The care team is available whenever the patient needs them through video visits or via in-app chat. Synchron Series B $40 The round was led by Khosla Ventures. The funding is expected to fuel a clinical study in the U.S. of Synchron's Stentrode system. The goal of the technology is to give individuals with paralysis the ability to control digital devices through thoughts. Proximie Series B $38 F-Prime Capital led the round. Existing investors Global Ventures, BECO Capital and Cedar Mundi Ventures participated in the round along with new backers Questa Capital, Eight Roads and Maverick Ventures. With its latest cash infusion, Proximie will continue growing into new markets, specifically in the U.S. and Europe. It also plans to invest in new technology capabilities through additional research and development. Proximie's technology-enabled platform uses augmented reality, machine learning and artificial intelligence to let clinicians remotely "scrub in" to operating rooms to participate in and help guide procedures in real time. Nayya Series B $37 The round was co-led by SVB Capital and ICONIQ Growth. Additional investors include Bow Capital, Felicis Ventures, Social Leverage SemperVirens, Guardian Strategic Ventures, Unum Business Ventures and CNO Financial Group. Nayya plans to use the new capital to grow its team and invest in new features for its platform, according to the announcement. Nayya’s platform helps employees first choose and enroll in benefits and then engage with their health plan. Cohere Health Series B $36 Polaris Partners, Longitude Capital, Deerfield Management, Flare Capital Partners and Define Ventures. The new funds are intended for Cohere’s digital health plan solutions, which offer a new approach to prior authorization systems. The aim is to create more collaborative care by automating provider and payer preauthorization. Cohere Health’s platform looks to put providers and health plans on the same page by creating an efficient, transparent system that aims to build low-cost, evidence-based care plans. NexHealth Series A $31 Jeffrey Katzenberg led the round with participation from Josh Buckley. The platform plans on using the money for growth. The San Francisco-based startup offers a full suite of technology tools to help provider practices manage both the patient-facing experience and back-end administrative processes. Stork Club Series A $30 The round was led by General Catalyst and included participation from existing investors Bowery Capital and Slow Ventures, as well as angel investors Jack Altman, founder of Lattice; Zach Sims, founder of Codecademy; Oleg Rogynskyy, founder of People.ai; and Kevin Mahaffey, founder of Lookout. The company did not specify what the funds would be used for. Stork Club is offered as an employee benefit to guide workers through the parenting journey, with services ranging from IVF and child adoption through postpartum recovery and newborn care. Syllable Series B $28 The round was led by Oak HC/FT with participation from previous investor Section 32. With the new cash, Syllable will scale its partnerships with health systems, deploy with payers and grow its team. The startup makes artificial intelligence-powered patient assistant products. Osso VR Series B $27 GSR Ventures led the round with participation from Signalfire, Kaiser Permanente Ventures, OCA Ventures, Scrum Ventures, Leslie Ventures and Anorak Ventures. The money will expand its library and platform capabilities. The company has designed a number of virtual reality educational training tools. Bicycle Health Series A $27 Questa Capital led the round, and City Light Capital, Emily Melton and previous investor SignalFire also participated in the raise. The new cash will go toward growing its clinician network, partnering with payers and conducting research into OUD. The company provides personalized treatment plans that include medication-assisted treatment (MAT) and behavioral health teletherapy in over 20 U.S. states. SymphonyRM Series B $25 The round was led by TT Capital Partners. Past investor Adams Street Partners also participated in the round. The company will invest the capital into sales and marketing to expand the use of its platform that helps provider and payer organizations engage patients with data and AI. SymphonyRM helps health systems transform how they acquire, engage and retain patients by creating an engagement model. Sesame N/A $24 Investments from new backers included Giant Ventures, Industry Ventures and Coefficient Capital, in addition to existing investors General Catalyst, Entree Capital and Atreides Management. The funds will support Sesame’s nationwide telehealth expansion and allow it to expand the scope of its in-person offerings. Using Sesame’s platform, patients can directly pay providers for a range of in-person or online care, including urgent care, sexual health and mental health. Vericred Series B $23 Aquiline Technology Growth, Echo Health Ventures, MassMutual Ventures, Guardian Strategic Ventures, Riverside Acceleration Capital, FCA Venture Partners and First Health Capital Partners. The company will pour the money into growing its team and building out its product line. The company has developed a suite of APIs that can be used across medical, life, dental, vision and other types of insurance. The service is able to help with power quoting, enrollment, member management and renewals. Artificial Series A $22 The round was led by M12, Microsoft’s venture fund, along with Playground Global and AME Cloud Ventures. The company will deploy the funds into product development, hiring additional team members and furthering its life science partnerships. Artificial is the maker of an automated platform for biopharma labs. Glytec N/A $21 Silicon Valley Bank, Savitr Capital and other private investors participated in the raise. The investments will go toward growing Glytec’s team, specifically across the engineering and product departments. Glytec’s eGlycemic Management System is centered on its FDA-cleared Glucommander algorithm. The algorithm uses real-time and historical patient data to personalize insulin dosing by learning each patient’s insulin sensitivity and estimating future needs. ZOE Series B $20 The round was led by Ahren Innovation Capital with additional participation from two-time Super Bowl champions Eli Manning and Ositadimma Umenyiora, along with Accomplice, THVC and Daphni. As the ZOE program is currently on a waitlist, the company plans to use the funds from its investment round to speed up the program’s rollout. Based on the results of ZOE’s at-home gut health, blood sugar and blood fat tests, the company creates a personalized dietary plan for its users. Liteboxer Series A $20 The round was led by Nimble Ventures. Other investors in the round included B. Riley Venture Capital, Raptor Group, Will Ventures and musician Timbaland. The company did not specify what the funds would be used for. The Boston-based company has created a boxing workout machine that gamifies exercise through flashing lights synced with music. Hawthorne Effect Series A $20 Northpond Ventures led the round with participation from SignalFire and P5 Health Ventures. The new money will go toward growing out the company, which has kept a relatively low profile since it was founded. Hawthorne was designed to help capture clinical trial data points beyond a single clinical setting. Assured Allies Series A $18.30 Core Innovation Capital and New Era Capital Partners led the round with participation from Wilton Re, LionBird Ventures and Harel Insurance. The company is looking to scale its product in the market. The company has created a platform that helps link seniors to health services. Mendel Series A $18 DCM led the round with participation from Olive Tree, Zola Global Investors, Millennium Technology Value Partners, Launch Capital, SOSV, Bootstrap Labs and independent investors. Mendel plans to use the infusion of cash to build out its business and sales team. Mendel uses AI to make sense of unstructured EHR data and clinical literature and provides analytical data to the end user. Canvas Medical N/A $17 The round was co-led by Inspired Capital and IA Ventures, with participation from IRONGREY and previous investors Upfront Ventures and iSeed. The company did not specify what the funds would be used for. The Canvas platform is designed to replace traditional electronic health records and physician practice management systems to help providers and insurers collaborate for value-based care. Renovia Series C-1 $17 The round included previous backers including Perceptive Life Sciences, Longwood Fund, Ascension Ventures and OSF Ventures, in addition to new investor Parian Global Management. Renovia said it plans to use the funds from its financing round to support the nationwide launch of the latest iteration of the leva Digital Therapeutic, which began in early April. Renovia's flagship product, leva, is an FDA-cleared digital therapeutic that helps women strengthen their pelvic floor muscles to treat urinary incontinence. Medchart Seed and Series A $17 The rounds were led by Crosslink Capital and Golden Ventures, with additional funds from Vast Ventures, Union Ventures, iGan Partners, Stanford Law School and Nas. The company says it will put the investments toward product innovation and hiring new talent. Medchart is a cloud-based health data platform. Sempre Health Series B $15 The round was led by Blue Venture Fund, the Blue Cross Blue Shield Association and Sandbox. Additional investors such as UPMC Enterprises, Rethink Impact, LifeForce Capital and Industry Ventures participated in the round as well. With the new funding, Sempre will build new partnerships with payers and pharma companies to expand its user base. Sempre offers patients discounts on their prescriptions when they refill them on time, with the hopes of improving medication adherence. Inbox Health Series A $15 Commerce Ventures, Vertical Venture Partners, Healthy Ventures, Collaborative Fund, Fairview Capital, CT Innovations and I2BF Global Ventures. The company said the funding will be used toward strategic growth and developing its billing system. The company is centered on personalizing patient billing. The technology was designed to automate bills and give patients additional insights into their charges. Spiras Series B $14 Global venture capital firm NEA spearheaded the funding while existing investors Altitude Ventures, FCA Venture Partners and other strategic investors also participated. The fresh cash will be applied to new market launches, the building of sales and marketing teams, R&D with technological development, and strengthening its management team. The company’s focus is on helping providers manage patients with chronic conditions. Providers can use the service for telehealth visits, digital communications and remote patient monitoring. Empathy seed $13 The round’s leading investors were General Catalyst and Aleph. The company did not specify what the funds would be used for. Empathy’s platform leads grieving families through end-of-life bureaucratic tasks such as arranging a funeral, validating a will, canceling accounts and cleaning out properties. Vector Remote Care Series A $12.5 Updata Partners The new funds will be used toward building out production, engineering and patient engagement. The company has created HIPAA-compliant software that is able to help capture data and help manage and analyze patients remotely. Seqster Series A $12 The round was led by OmniHealth Holdings LLC. Takeda Digital Ventures and 23andMe CEO and founder Anne Wojcicki also participated in the financing round. With the new investment, Seqster will continue growing and evolving its tech-enabled platform. The company’s platform combines patient data from their medical history, genetic background and metrics collected by health wearables into one HIPAA-compliant platform. Form Health Series A $12 The round was led by M13 with participation from SignalFire and NextView Ventures. Form plans to use the funding to fuel company growth. The company provides personalized virtual weight loss care to consumers across 21 states. TRIPP Series A $11 Vine Ventures and Mayfield led the round with equal participation from Integrated. The company said it plans to use the new funds to build out its team and user base. It is also looking to grow its R&D efforts and expand to support cross-platform distribution. The company has created software that presents psychedelic visuals, target sounds and interoperations through a virtual reality headset. Virti Series A $10 IQ Capital led the round joined by Cedars-Sinai Medical Center and a new, U.K.-based learning technology VC fund. Virti will use the Series A funding to support company growth and research and development into new training technologies. The company is a digital training platform. Real Series A $10 The round was led by Lightspeed Venture Partners. With the newly raised capital, Real will continue investing in the growth of its platform and membership. Real takes an on-demand approach to therapy. Ride Health N/A $10 Topmark Partners led the round along with an equity investment from Excelerate Health Ventures and debt financing from Bridge Bank. Existing investors Activate Venture Partners and Newark Venture Partners also participated in the raise. Ride Health plans to put the new proceeds into company growth, specifically through expanding its national network and by investing in its benefits management system and platform APIs. The Ride Health platform manages end-to-end NEMT, from automated ride-scheduling to passenger performance ratings. Legacy Series A $10 FirstMark Capital Legacy plans to use the new funds to increase its geographical footprint and expand to more patients. Legacy is born out of the Harvard Innovation Labs incubator program and focuses on helping men understand their fertility. Alife seed $10 Lux Capital led the round with participation from Amplo, IA Ventures and Springbank Collective. Also included in the raise were a number of angel investors, including Anne Wojcicki, the founder and CEO of 23andMe; Fred Moll, the founder of Intuitive Surgical and Auris; Amira Yahyaoui, the founder of Mos and Sequoia Scout; Arthur Patterson the founder of Accel; Dr. Tom Lee the founder of One Medical Group and Galileo Health; and the founders of Ramp and Headway. The company will use the new funds to build out the Alife team and to prepare the technology for regulatory review Founded in 2020, Alife has yet to release any products, but the company plans to create artificial intelligence-enabled software to assist in vitro fertilization. XRHealth N/A $9 Discount Tech The new money will go toward expanding XRHealth's sales and marketing initiatives in the U.S., Australia and Israel. The startup calls itself an "extended reality" company and has made virtual health clinics that employ both VR and AR tools, as well as data analytics. AcuityMD N/A $7 The round was led by Benchmark, with participation from Ajax Health. The funding will go toward hiring, as AcuityMD works to double its team this year. It will also invest in product development, according to the announcement. The AcuityMD platform combines medical device data from sales to patient outcomes so that manufacturers can track the performance of their products. Olive Union Series B $7 Beyond Next Ventures, Bonds Investment Groups and Japan Policy Finance Corporation The company plans to use the new funds to expand its product line and create new technologies for hearing health. Olive Union's earbuds are direct-to-consumer products that use artificial intelligence to isolate unwanted noises and enhance music, conversations, TV and other sounds. BioT Seed round $7 emocha Health Series A $6 The round was led by Claritas Health Ventures. Healthworx, Kapor Capital and PTX Capital also invested in the round. emocha said it will use the capital to support integrations and to grow its remote clinical team of nurses and pharmacists that help users stay on top of their medication regimen. emocha is a medication adherence platform. BeatO N/A $5.7 W Health Ventures led the round with participation from Threpsi Solutions' e-pharmacy unicorn PharmEasy, Merisis VP and previous investors. It will use its new funds to grow its subscriber base across multiple channels and locations and enhance product offerings for cardiometabolic conditions. BeatO is a mobile health application for chronic disease management. UCM Digital Health Series A $6 Armory Square Ventures led the round with additional participation from Contour Ventures and River Park Ventures. With the new investments, UCM Digital Health will continue its company growth. The company’s digital-first platform provides urgent and emergent care, virtual primary care and home testing. Wysa Series A $6 The round was led by W Health Ventures. The Google Assistant Investment program and existing investors pi Ventures and Kae Capital also participated in the financing round. The funding will go toward scaling Wysa’s sales team and therapist network, as well as building out its employer offering. Wysa’s platform deploys an AI chatbot that uses cognitive behavioral therapy techniques to help users with their stress, depression and anxiety. DeepScribe seed $5 Bee Partners led the round with additional participation from new backers Industry Ventures and Stage II Capital, along with existing investors Tsingyuan Ventures, 1984 Ventures, Wavemaker 360, Supernode Ventures, Skydeck, Plug and Play, and Sequoia Scout Fund. DeepScribe will use the funds to accelerate company growth by building out its machine learning and product engineer team as well as its sales and implementation teams. The scribing tool combines natural language processing with deep learning processes to listen when doctors interact with their patients, take notes on the conversations and transfer the summary into a compliant note in the doctor’s EHR system. MindPortal seed $5 The round was led by Learn Capital. Other investors include Kleiner Perkins; Dan Siroker, founder and CEO of Scribe AI; Matt Bellamy, frontman of Muse; James Park, cofounder and CEO of Fitbit; Julie Zhou, cofounder of Sundial; Scrum Ventures; and additional angel investors. The company will use the capital to hire additional neuroscientists, product engineers and machine learning experts. MindPortal’s wearable device records brain activity in real time. Its not-yet-released platform will allow users to engage with immersive virtual reality experiences and create their own with their thoughts alone. Naluri Series A $5 Integra Partners of Singapore and previous investors Duopharma Biotech Berhad, Pathology Asia (via Biomark) and M Venture Partners participated in the round. Naluri said it will use its fresh funds to launch its service in Thailand and the Philippines, as well as expand its operations in Singapore and Indonesia. Naluri offers human-led and AI-augmented digital health coaching for people with chronic diseases such as renal disease, cancer, diabetes, hypertension and heart disease, as well as mental health conditions like anxiety and depression. Orchid seed $5 Investors include Refactor Capital, Village Global, Day One Ventures, Olive Capital and Boom Capital along with the leaders of 23andMe, Counsyl, Clover Health, Coinbase, Eventbrite, Flatiron, Oscar Health and Stellar. The company did not specify what the funds would be used for. Using an at-home saliva test kit, Orchid detects whether a couple's future child will be at an elevated or normal genetic risk for diseases such as heart disease, stroke, schizophrenia, Alzheimer's disease, breast cancer, prostate cancer, diabetes and more. Nirvana Health N/A $4 Eniac Ventures and Arc Ventures participated in the round. With the new capital, Nirvana hopes to scale its platform to onboard additional clients. The company operates a practice-management platform for therapists that streamlines the administrative tasks of their business. Docbot Series A $4 Docbot’s latest funding raise was led by Khosla Ventures with participation from Bold Capital Partners, the Collaborative Fund and Boutique Venture Partners. The new cash will go toward clinical trial development for UltivisionAI as the company seeks FDA clearance. The company’s lead product, UltivisionAI, can be used in real time to help clinicians detect and diagnose GI disease. Veri N/A $4 The round included investments from its pre-seed and seed rounds, which were led by Lifeline Ventures and PROfounders Capital, respectively. Accel also participated in the round as well as angel investors Kristian Ranta, the founder and CEO of Meru Health; and Johannes Schildt, the cofounder and CEO of Kry. The company did not specify what the funds would be used for. Veri is a metabolic health platform that pairs with the Abbott Freestyle Libre to give users insights into how their diet affects their health. MD Ally seed $4 General Catalyst led the round with participation from Seae Ventures. The company did not disclose what the funds would be used for. The MD Ally platform allows 9-1-1 operators to transition emergency calls to a licensed medical professional who can administer virtual care. NUE Life Health seed $3.3 N/A The company did not specify what the new funds would be used for. The company created a companion app to help guide users through their psychedelic-assisted therapies, including a home-based ketamine treatment. Valeo Wellbeing seed $3 The funding was led by Global Founders Capital, Global Ventures, Nuwa Capital and FJ Labs. The funding was led by Global Founders Capital, Global Ventures, Nuwa Capital, and FJ Labs. Valeo created a personalized health tracking and guided wellbeing app. ExplORer Surgical N/A $3 The round was led by Aphelion Capital and had support from the company’s previous backers, in addition to new investors like Sofia Fund. The funds from this round will be used to add new technological capabilities to its platform and to hire new team members. The ExplORer platform gives surgical teams a “digital playbook” to guide them through operations. It provides a step-by-step, role-specific procedural workflow designed to increase surgeon preparedness and better patient outcomes. Votive Health N/A $3 Flare Capital Partners led the round with Chrysalis Ventures and OCA Ventures as additional participants. Votive plans on using the capital to accelerate its growth and scale its offering. The company plans to use its technology platform to coordinate value-based arrangements between payers and providers to deliver at-home care for people dealing with life-threatening illnesses. Oath Care seed $2 Investors include XYZ Venture Capital, General Catalyst, Muse Capital and Eros Resmini, the founder and managing partner of the Mini Fund. Oath said it will use the funds to hire additional team members and accelerate product development ahead of its launch. Oath’s first offering is a subscription service where parents can participate in small groups made up of people in similar stages of pregnancy, and with similar ages, locations and careers, led by a trained facilitator. Ksana Health seed $2 re.Mind Capital led the round with additional participation from WPSS Investments, Panoramic Ventures, the Telosity Fund, Palo Santo Venture Fund and Able Partners. Ksana did not specify what the funding would be used for. The company’s latest digital health solution, Vira, will be piloted the Anthem Digital Incubator. Vira converts quantifiable behavioral patterns collected by smartphones into actionable and objective insights for practitioners and their patients. Mantra Health seed $2 Canaan Partners, City Light Capital, Baleon Capital, as well as Aligned Telehealth founder Dr. Nitin Nanda as a strategic angel investor. Mantra said that the new funds would help the company accept health insurance from additional major carriers. Further, the money will support its service expansion into all 50 U.S. states and Washington, D.C., in time for the fall semester. Mantra bolsters colleges' and universities' on-campus health resources with a "closed-loop" virtual mental health offering that aims to ensure continued support and follow-up. Thrivable N/A $2 Allos Ventures, JumpStart, North Coast Ventures and Early Light Ventures participated in the round. The capital will be put toward growing its team of full-time employees with a focus on the areas of technology, research, data science, sales and marketing. The company helps healthcare companies complete surveys, interviews, usability studies and focus groups by giving them the tools to create them and then distributing them to its on-demand panel of patients. Ronovo Surgical Series A undisclosed Matrix Partners China and Vivo Capital The proceeds from the investing round will be used to quickly develop technologies, as well as "pursue multiple global strategic partnerships in support of accelerated path to commercialisation," said Ronovo CEO and founder Dr. John Ma in a statement. Staffed by surgeons, medtech veterans and robotics experts, the 2-year-old company aims to “democratise” digital and minimally invasive surgery (MIS) in the “vastly underserved” Chinese surgical market. $6,207